• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LIU Yuhai,ZHANG Jiachen,LIU Jinyi,XIAO Yan.Research progress on new drug combinations and personalized treatment for clinical cure of chronic hepatitis B[J].Journal Of Pharmaceutical Research,2026,45(5):577-586[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1689times   Download 761次 QR Code for this article
Scan with your phone!
慢性乙型肝炎临床治愈新药组合与个性化治疗研究进展
刘宇海1,张嘉辰1,刘金毅1,肖妍2
Font:Larger+|Default|Smaller-
(1.北京三元基因药业股份有限公司,北京 102600;2.中国食品药品检定研究院,北京 100050)
摘要:
本综述聚焦慢性乙型肝炎临床治愈领域,着重探讨新型药物组合在个性化治疗中展现的巨大潜力。随着对慢性乙型肝炎发病机制理解的深入,新型药物研发取得显著进展。不同作用机制的药物巧妙组合,如靶向病毒复制关键环节的药物与调节宿主免疫反应的药物联用,为实现临床治愈开辟了新路径。考虑到患者在基因多态性、免疫状态及疾病进展阶段等方面的个体差异,依据患者特征精准匹配药物组合的个性化治疗策略,已成为当下研究热点。文章全面梳理相关研究成果,详细分析新型药物组合的疗效、安全性,以及个性化治疗中药物选择与应用的实施路径和面临的挑战,旨在为慢性乙型肝炎临床治愈的进一步探索提供坚实的药物应用理论依据与实践参考,助力优化基于药物的治疗方案,切实提升患者临床治愈的可能性。
关键词:  慢性乙型肝炎  临床治愈  新型药物组合  个性化治疗
DOI:10.13506/j.cnki.jpr.2026.05.014
基金项目:
Received Date:May 27, 2025   Revision Date:July 09, 2025   Publication Date:May 29, 2026
Research progress on new drug combinations and personalized treatment for clinical cure of chronic hepatitis B
LIU Yuhai1,ZHANG Jiachen1,LIU Jinyi1,XIAO Yan2
(1.Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.,Beijing 102600,China;2.National Institutes for Food and Drug Control,Beijing 100050,China)
Abstract:
This review focused on the field of clinical cure of chronic hepatitis B, with an emphasis on exploring the great potential of novel drug combinations in personalized treatment. With the deepening of the understanding of the pathogenesis of chronic hepatitis B, significant progress has been made in the research and development of new drugs. The ingenious combination of drugs with different mechanisms of action, such as the combination of drugs targeting key links of viral replication and drugs regulating the host immune response, has opened up a new path for achieving clinical cure. Considering the individual differences among patients in terms of genetic polymorphism, immune status, and disease progression stage, the personalized treatment strategy of precisely matching drug combinations based on patient characteristics has become a current research hotspot. This article comprehensively combs through relevant research achievements, and conducts a detailed analysis of the efficacy and safety of novel drug combinations, as well as the implementation paths and challenges faced in the selection and application of drugs in personalized treatment. It aims to provide a solid theoretical basis and practical reference for drug application for the further exploration of clinical cure of chronic hepatitis B, facilitate the optimization of drug-based treatment regimens, and effectively improve the possibility of clinical cure for patients.
Key words:  Chronic hepatitis B  Clinical cure  Novel drug combinations  Personalized treatment
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.